Treatment of metastatic hormone‐sensitive prostate cancer

Abstract

Men with metastatic prostate cancer have a significantly reduced median five‐year survival compared with that associated with the cancer overall. Clinical trials are exploring the most effective treatment strategies for metastatic hormone‐sensitive prostate cancer to intervene before transformation to castration‐resistant prostate cancers when options are limited.

Related Papers

• → Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer(1993)798 cited
• → Murine Prostate Micro-dissection and Surgical Castration(2016)23 cited
• → Murine Prostate Micro-dissection and Surgical Castration(2016)13 cited
• → Metastatic phenotype in CWR22 prostate cancer xenograft following castration(2015)10 cited
• → A glimpse at the future of some endocrine aspects of prostate cancer(1996)5 cited